118 related articles for article (PubMed ID: 23206458)
1. Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal.
Wang G; Zhu Z; Lei C; Li M; Liu F; Mao Y; Yu Z; Liu M; Zhao X; Tang T
J Int Med Res; 2012; 40(5):1761-74. PubMed ID: 23206458
[TBL] [Abstract][Full Text] [Related]
2. Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells.
Casado-Díaz A; Santiago-Mora R; Dorado G; Quesada-Gómez JM
Arch Med Res; 2013 Jul; 44(5):325-34. PubMed ID: 23867791
[TBL] [Abstract][Full Text] [Related]
3. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
Jin J; Wang L; Wang XK; Lai PL; Huang MJ; Jin DD; Zhong ZM; Chen JT; Bai XC
J Surg Res; 2013 Mar; 180(1):e21-9. PubMed ID: 22487394
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats.
Ye T; Cao P; Qi J; Zhou Q; Rao DS; Qiu S
PLoS One; 2017; 12(10):e0186012. PubMed ID: 29045447
[TBL] [Abstract][Full Text] [Related]
5. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
Follet H; Li J; Phipps RJ; Hui S; Condon K; Burr DB
Bone; 2007 Apr; 40(4):1172-7. PubMed ID: 17240209
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
Matsumoto T; Nagase Y; Iwasawa M; Yasui T; Masuda H; Kadono Y; Nakamura K; Tanaka S
Arthritis Rheum; 2011 Dec; 63(12):3908-17. PubMed ID: 21898348
[TBL] [Abstract][Full Text] [Related]
7. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
[TBL] [Abstract][Full Text] [Related]
8. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.
Fujita H; Kurokawa K; Ogino T; Ono M; Yamamoto M; Oka T; Nakanishi T; Kobayashi N; Tanaka N; Ogawa T; Suzaki E; Utsumi K; Sasaki J
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):78-84. PubMed ID: 21332944
[TBL] [Abstract][Full Text] [Related]
9. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
D'Amelio P; Grimaldi A; Di Bella S; Tamone C; Brianza SZ; Ravazzoli MG; Bernabei P; Cristofaro MA; Pescarmona GP; Isaia G
J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate on bone marrow adipocytes in postmenopausal women.
Duque G; Li W; Adams M; Xu S; Phipps R
Osteoporos Int; 2011 May; 22(5):1547-53. PubMed ID: 20661545
[TBL] [Abstract][Full Text] [Related]
11. Bone-protecting effect of Rubus coreanus by dual regulation of osteoblasts and osteoclasts.
Do SH; Lee JW; Jeong WI; Chung JY; Park SJ; Hong IH; Jeon SK; Lee IS; Jeong KS
Menopause; 2008; 15(4 Pt 1):676-83. PubMed ID: 18709701
[TBL] [Abstract][Full Text] [Related]
12. 8,8''-Biapigeninyl stimulates osteoblast functions and inhibits osteoclast and adipocyte functions: Osteoprotective action of 8,8''-biapigeninyl in ovariectomized mice.
Siddiqui JA; Swarnkar G; Sharan K; Chakravarti B; Sharma G; Rawat P; Kumar M; Khan FM; Pierroz D; Maurya R; Chattopadhyay N
Mol Cell Endocrinol; 2010 Jul; 323(2):256-67. PubMed ID: 20380869
[TBL] [Abstract][Full Text] [Related]
13. Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Iwamoto J; Matsumoto H; Takeda T; Sato Y; Liu X; Yeh JK
Calcif Tissue Int; 2008 Aug; 83(2):121-8. PubMed ID: 18543014
[TBL] [Abstract][Full Text] [Related]
14. The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.
Valenti MT; Giannini S; Donatelli L; Zanatta M; Bertoldo F; Sella S; Vilei MT; Ossi E; Realdi G; Lo Cascio V; Dalle Carbonare L
Arthritis Res Ther; 2010; 12(4):R163. PubMed ID: 20738860
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Iwata K; Li J; Follet H; Phipps RJ; Burr DB
Bone; 2006 Nov; 39(5):1053-1058. PubMed ID: 16807159
[TBL] [Abstract][Full Text] [Related]
16. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Aug; 87(8):525-6. PubMed ID: 20180356
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
18. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
Thouverey C; Caverzasio J
Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
20. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells.
Rickard DJ; Wang FL; Rodriguez-Rojas AM; Wu Z; Trice WJ; Hoffman SJ; Votta B; Stroup GB; Kumar S; Nuttall ME
Bone; 2006 Dec; 39(6):1361-72. PubMed ID: 16904389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
